Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the ...
Savara has a one year low of $2.44 and a one year high of $5.70. The firm has a market cap of $423.90 million, a P/E ratio of -5.74 and a beta of 0.63. SVRA has been the topic of several recent ...
LANGHORNE, Pa., March 03, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback